Phil7777777777
Posted - 9 minutes ago
$VKTX
biolover
Posted - 13 minutes ago
$VKTX this statement show your bias and lack of knowledge on how Viking ran the glp1 gip program so far. They accrued 200 patients in less than a week for phase 2 ( don’t know what I need to repeat that since you are expert on the topic and u did your homework but for new people here that you are trying to confuse) . The phase iii will likely start this year as they are probably already negotiated with sites and likely written the protocol. They Will accrue 3000 pt in 1-2 months and they can have placebo or tirzapetide or whatever you want them to beat as control arm. They will run it for a year and report data in late 2025 or early 2026. And subsequently purse FDa approval. I personally believe they will be bought or partnered much sooner than that . Imminent.
TrustButVerifi
Posted - 18 minutes ago
$VKTX Why would anyone who has no invested interest in this ticker show up and post any fkn comment in this thread? For your well-being? Incomprehensible!
Fk ‘m ! Either you re Long or Short!
Don’t pretend you re here looking out for humanity!
If you ve that kind of time Go Volunteer at the homeless shelter!
TrustButVerifi
Posted - 23 minutes ago
$VKTX Omg! There we go again! We got a biotech John who claims he has been in the industry for 20 years and Just woke up to discover VK2735.WTF Dude.
There are squirrels here who never took a biology class and invested in Viking 5 yrs ago. How the F 20 yrs in the industry and you just woke here. Give me a fkn break!
NYC_SUPAPUMPA_9B
Posted - 1 hour ago
$VKTX $TERN $ALT $RHHBY Anyone could verify that Roche had 14 cohorts & all they released is one(best) most likely maxed out because of tolerance issue? I came across this statement over x.com I am not a MD or health science expert so what I understood from Roche PR is the opposite to this statement, that the data were for all cohorts except one to be published later.
Chartsgalore
Posted - 1 hour ago
$VKTX "Viking could be sitting on a gold mine. William Blair analyst Andy Hsieh projects VK2735 peak sales of $14.4 billion in the U.S. and an additional $7.2 billion in Europe, thanks to the enormous commercial opportunity inherent in the weight loss care market. These astronomical sales figures are remarkable for a company with an $8.1 billion market cap." **Enterprise Value now sits at $6.43 Billion after the recent stock decline.
Chartsgalore
Posted - 1 hour ago
$VKTX Viking management will meet with the FDA for a Type C meeting sometime in the next few weeks where they will be given the go ahead to start a VK2735 Phase 3 trial or be required to conduct another Phase 2b. I don't see how or why the FDA would request another Phase 2 trial given the very benign safety profile thus far in all trials. An FDA Phase 3 OK would be a major catalyst as it would reduce the time to market. It could be that the various pharmas Viking is currently having discussions with are waiting for the results of this meeting before making a move(partnership/acquisition).
inv1ncible
Posted - 3 hours ago
$VKTX
BiotechJohn
Posted - 4 hours ago
$VKTX will need a good 5 years to generate the phase 3 data and get approval, there won't be a priority review here by FDA.
Semaglutide goes generic in 2031 unless they can get an extension.
For molecules with relatively high biosimilar uptake (>60%), prices fell considerably (-21.2% to -59.3%) one year after exclusivity milestones
https://pubmed.ncbi.nlm.nih.gov/35965481/#:~:text=For%20molecules%20with%20relatively%20high,2.4%25%20to%20%2D8.4%25).
Hard to see how a prospective buyer makes anything here unless the data is stunning.
OnTheBalance
Posted - 4 hours ago
$VKTX worth a re-post ✅
biolover
Posted - 4 hours ago
$VKTX the market for glp1 gip dual agonist will be much more than 100 B by 2030. By looking at cardiovascular , neurological and myriad other benefits. I hear the current obesity penetration is 1-5 % ( 1% according to novo CEO) and Lilly and novo together expected to sell 30-40 Billion of glp1 / dual drugs during 2024 with still very low penetration and drug shortage and with largely out of pocket coverage and with no outcome FDA approved indications
And the benefit to society is much more than that number
biolover
Posted - 4 hours ago
$VKTX and the benefit will be more with glp1 gip dual agonists. Roche news regardless of details should have been a real blow to Novo and not to Viking . Novo could get in trouble 5 years down the line if not acting now ( some of novo leadership probably know that ) The combo with amylin agonist is not the solution. They are missing big on the best wt loss class which is the dual agonists.
BioST
Posted - 5 hours ago
$VKTX using MACD, RSI & SMA as technical analysis & generally speaking what is the correct time frame / candle time one should mostly rely to target entry. I am just learning & notice different combinations can give you different perspective. My guess is that there’s not a one size fits all but wondering what is generally most reliable? Ty
BigElvis_GTown
Posted - 5 hours ago
@blewmyorigin the other point was this was a similar formula to $VKTX and $alt is different and from what I read superior.
DieHaendezumHimmel
Posted - 10 hours ago
$VKTX Lets see how this plays out. There´s still a long road ahead
whatshares
Posted - 10 hours ago
$VKTX I am curious to know which of all the BP are interested buying VKTX, maybe MRK, NOV, BAYER or ... ???
Phil7777777777
Posted - 13 hours ago
$VKTX
BeyondtheCouch
Posted - 15 hours ago
$VKTX anyone else reading that Roche had 14 cohorts and only released data from 1 and that was without full tolerability data. Smoke and mirrors
Chartsgalore
Posted - 15 hours ago
@bavariaron @TraderRapp FDA meeting will be sometime in June, that's another big catalyst for $VKTX Can't see why FDA would require another Phase 2 with VK2735 excellent safety profile and availability shortage of GLP-1 drugs in the market
kellyCriterion101
Posted - 15 hours ago
$VKTX Pretty good read https://www.nature.com/articles/s41591-024-02996-7 very repeatable in GLP-GIP type drugs. In late December I was present when they showed partially mature SELECT data on CV benefit and it seemed to not benefit (on a statistically significant basis) those who are super obese. But this mature data set says otherwise. Of course, this is all baked well into VKTX, but one thing is for certain, GLP-GIP drugs will only get bigger and get more coverage from payers and state. The value of making sure the obese person in your family lives long enough to see their lineage's kids is immeasurable. A reduction in CV events is not something you can ignore. I continue to think the synergy of VK5211 and VK2735 are a complete package for a buyer to negotiate with VKTX and $LGND to own the asset. My ass is burnt this week for sure along with other longs, my average is 63, while the other LT guys here are in from <30. I would buy up here but my exposure is huge. Drawdown sucks, but I know what I hold. Do you?
DG20
Posted - 16 hours ago
$VKTX This makes ZERO SENSE and whoever wrote it is either extremely stupid or a complete liar. There is oral semaglutide it’s called Rybelsus. VK2809 is NOT a weight loss drug and does NOT even cause weight loss. VK2809 is the BETA portion of the thyroid hormone T3 (triiodothrionine). You do not want VK2809 to cause weigh loss because it would be systematically active, it’s focused amazing ONLY ON THE LIVER…
Phil7777777777
Posted - 16 hours ago
$VKTX
radham
Posted - 17 hours ago
$VKTX back to $80 next week
JGNYC
Posted - 17 hours ago
$MDGL trying enter poots here ride it down below $200 when $VKTX drops Nash data
TraderRapp
Posted - 17 hours ago
$VKTX when does the ph3 trial for injectable start? Any reason to think Viking is waiting on this?
Phil7777777777
Posted - 18 hours ago
$VKTX
Tradelearner2022
Posted - 18 hours ago
$VKTX -VK2809 is a pill. None of the leading weight-loss drugs is currently available in pill form. The first commercialized weight-loss pill is almost certain to be a blockbuster. Viking Therapeutics is in the running. It’s hard to bet against the stock at this point.
Oregontech
Posted - 18 hours ago
$VKTX Remember. The bog boys loaded up on the secondary offering at$85 https://www.prnewswire.com/news-releases/viking-therapeutics-announces-closing-of-public-offering-of-common-stock-including-full-exercise-of-underwriters-option-to-purchase-additional-shares-302078953.html This is a huge discount. Almost a 15% Discount in two days here. And almost a 25% discount from the offering in March. The trend will be $120 plus.